Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines
Completed · Phase 1
Conditions studied: Bacterial Infections, Group B Streptococcus
In brief
The purpose of this study is to test the safety and favorable immune response to an anti-streptococcal vaccine (a vaccine that treats a common bacterial infection) in healthy non-pregnant women. Group B Streptococcus (GBS) continues to be the single most frequent cause of life-threatening bacterial infection during the first 2 months of life. Further, GBS pregnancy-related morbidity afflicts more than 50,000 women annually in the US. Therefore, active immunization of women is an appealing strategy for the prevention of GBS disease in pregnant women and their infants during the first 3 months of infant life.
Key facts
- Study ID
- NCT00008853
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 65
- Expected to finish
- 2005-11-01
- Last updated by the study team
- 2010-08-27
Who can join
Age: 18 and older, up to 45. Sex: female. Healthy volunteers: accepted.
Where it is running
- AIDS Ctr — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.